Hypothesis

Individual differences in experimental pain sensitivity reflect the state of systemic aging because nociceptor excitability is tuned by mitochondrial NAD⁺‑sirtuin signaling and inflammasome‑driven cytokine exposure, both of which deteriorate with age. Consequently, a quantitative sensory testing (QST) protocol measuring pressure‑pain threshold (PPT) and heat‑pain threshold (HPT) will correlate with epigenetic age clocks (e.g., GrimAge, DunedinPoAM) beyond chronological age, and genetic variants in nociceptive genes will causally influence these clocks via inflammasome pathways.

Mechanistic Rationale

• Mitochondrial dysfunction in dorsal root ganglion (DRG) neurons reduces NAD⁺ levels, lowering SIRT1 activity. Reduced SIRT1 deacetylates NF‑κB p65, amplifying transcription of pro‑inflammatory cytokines (IL‑1β, TNF‑α) that sensitize TRPV1 and Nav1.7 channels, decreasing pain thresholds. The same NAD⁺‑SIRT1 axis governs hepatic and muscular oxidative metabolism, linking peripheral pain sensitivity to tissue‑specific mitochondrial health {https://pmc.ncbi.nlm.nih.gov/articles/PMC12266770/}.
• Inflammasome activation (NLRP3) in microglia and DRG releases caspase‑1‑processed IL‑1β, which further phosphorylates Nav1.8 via p38 MAPK, lowering action‑potential thresholds. Chronic low‑grade inflammasome signaling is a hallmark of aging and predicts frailty independent of traditional biomarkers {https://pmc.ncbi.nlm.nih.gov/articles/PMC10410004/}.
• Vagal anti‑inflammatory tone, indexed by heart‑rate variability, suppresses NLRP3 activation via acetylcholine‑α7nAChR signaling. Low vagal tone therefore coincides with heightened pain sensitivity and accelerated epigenetic aging, providing a triadic link between autonomic function, nociception, and biological age.

Testable Predictions

1. In a cohort of adults aged 30‑80, PPT and HPT will show inverse associations with GrimAge acceleration (β ≈ –0.15 per SD, p < 0.001) after adjusting for sex, BMI, and smoking.
2. Longitudinal decline in PPT/HPT over two years will predict increase in DunedinPoAM velocity, even when baseline epigenetic age is accounted for.
3. Mendelian randomization using GWAS‑derived instruments for SCN9A (rs6746030), COMT (rs4680), and TRPV1 (rs8065080) will demonstrate a causal effect of lowered pain sensitivity on reduced GrimAge acceleration (IVW estimate < 0, F‑statistic > 20, pleiotropy‑robust).
4. Pharmacological NAD⁺ supplementation (e.g., NR) in older mice will raise PPT/HPT and attenuate GrimAge‑like epigenetic shifts in liver and muscle, confirming the mechanistic node.

Analytical Plan

• Recruit 500 participants, conduct QST with algometer and thermode, collect blood for DNAm arrays, compute GrimAge and DunedinPoAM.
• Perform linear mixed models for cross‑sectional and longitudinal associations.
• Obtain SNP‑pain sensitivity summary statistics from publicly available GWAS (e.g., UK Biobank pain phenotype) and apply two‑sample MR with Steiger filtering, IVW, MR‑Egger, and weighted median.
• Validate findings in an independent cohort (n = 300) and in mouse models using conditional SIRT1 knockout in DRG neurons.

Potential Confounders & Mitigation

• Acute inflammation or injury will be excluded via CRP < 3 mg/L and self‑report of recent trauma.
• Medications affecting pain (opioids, gabapentinoids) will be recorded and used as covariates.
• Population stratification will be controlled with principal components in MR.

If the hypotheses hold, pain sensitivity could serve as a low‑cost, high‑throughput proxy for biological age, complementing existing clocks and revealing novel intervention targets (NAD⁺ boosters, inflammasome inhibitors).